Repaglinide in the management of new-onset diabetes mellitus after renal transplantation.

Abstract

The purpose of this study was to investigate the use of the short-acting insulin secretion drug repaglinide in new-onset diabetes mellitus (NODM) after renal transplantation. Twenty-three Caucasian patients with NODM after renal transplantation were selected to receive repaglinide therapy and were followed for at least 6 months. A control group treated with rosiglitazone was chosen for comparison. Successful repaglinide treatment was defined as a significant improvement of blood glucose concentrations and HbA1c <7% in the absence of glucosuria and without the need for the addition of further anti-diabetic agents. After 6 months of treatment with repaglinide, 14 of the 23 patients were successfully treated. Mean HbA1c decreased from 7.6 +/- 0.6% to 5.8 +/- 0.6% in 14 patients treated successfully. In nine patients, hyperglycemia persisted, and they were switched to insulin treatment (HbA1c 8.5 +/- 2.9% at the beginning to 7.4 +/- 2.2%). Mean serum creatinine levels, cyclosporine A and tacrolimus blood levels did not change significantly following institution of repaglinide therapy. The rate of successful treatment and the degree of HbA1c decrease were similar compared to rosiglitazone-treated control patients. The data from our observational study indicate that repaglinide can be an effective treatment option in Caucasian patients with NODM after renal transplantation.

• Authors: T Türk, F Pietruck, S Dolff, A Kribben, O E Janssen, K Mann, T Philipp, U Heemann, O Witzke
• Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (Am J Transplant) Vol. 6 Issue 4 Pg. 842-6 (Apr 2006) ISSN: 1600-6135 [Print] United States
• PMID: 16539642 (Publication Type: Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Carbamates
• Hypoglycemic Agents
• Piperidines
• Thiazolidinediones
• Rosiglitazone
• repaglinide

Topics

• Carbamates (therapeutic use)
• Diabetes Mellitus (drug therapy)
• Female
• Humans
• Hypoglycemic Agents (therapeutic use)
• Kidney Transplantation
• Male
• Middle Aged
• Piperidines (therapeutic use)
• Rosiglitazone
• Thiazolidinediones (therapeutic use)
• Treatment Outcome